Healthcare

The post-earnings trend says the stock will drop after the report.
What to do when central bankers tell you to cut risk.
A lower price means more value for this high-quality stock.

Take a Yellen Opportunity Real Money Pro($)

There's a great entry point in Celgene at $84.
It is preserving its Copaxone franchise, and the executive changes are good news.
Cheap money and greed from the Allergan bidder's side are strong incentives.
A wave of M&A in the health sector makes sense.
Forget marijuana, there's a more basic reason to be bearish.
The stock seems liable to reenter its uptrend, so here's how to play it.
Borrowing a page from a master investor's playbook.

Columnist Conversations

FB is trading $75.88, up 6.4% with IV30™ down 33.4%. This is a follow up to the post yesterday: FB - Ear...
Bloomberg reporting around 2pm ET Zillow for Trulia...Z declined to comment, TRLA won't comment on spec. Few t...
With just over 40% of S&P 500 components having reported 2Q earnings, 158 of them or about 77% have surpri...
DHI is the biggest loser in the S&P 500 today. The homebuilder is off over 10% on its heaviest downsi...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.